



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent:	Anti-HIV-1 gp120 Monoclonal (VRC01)
Catalog Number:	12033
Lot Number:	160008
Release Category:	C
Provided:	500 µg of purified antibody at 3 mg/mL in PBS, pH 7.2 Purity: ~95% by densitometric analysis of the Coomassie Blue-stained SDS-PAGE gel Endotoxin Level: 0.8 EU/mg
Description:	A recombinant monoclonal antibody to HIV-1 gp120, specifically the CD4-binding site
Host:	Human
Titer:	The user should determine the optimal concentration for any application.
Special Characteristics:	This recombinant antibody was produced in a 293-6E expression system and purified by Protein A sepharose column chromatography. This antibody originates from the B-cells of a HIV-1 infected donor. VRC01 neutralizes a broad variety of laboratory HIV-1 strains and primary isolates and is active against all major subtypes.
Recommended Storage:	Keep the reagent at 4°C for short term storage and at -80°C for long term storage. Avoid freeze-thaw cycles as reagent degradation may result.
Contributor:	Xueling Wu, Zhi-Yong Yang, Yuxing Li, Gary Nabel, John Mascola
Isotype:	IgG ₁ κ

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

References:

Wu, X., Yang, Z. Y., Li, Y., Hogerkorp, C. M., Schief, W. R., Seaman, M. S., . . . Mascola, J. R. (2010). Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. *Science*, 329(5993), 856-861. doi:10.1126/science.1187659 [PUBMED](#)

NOTE:

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Anti-HIV-1 gp120 Monoclonal (VRC01), from Dr. John Mascola (cat# 12033)." Also include the reference cited above in any publications.

Scientists at for-profit institutions or who intend commercial use of this reagent must contact NIAID Technology Transfer and Intellectual Property Office at the following email address: NIAIDAIDSReagent@niaid.nih.gov, before the reagent can be released.

Last Updated

December 19, 2018

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.